Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680616 | 0.88 | PLK1 (0.59) | PLK1EGLN1ALDH1A1RAB9AHDAC1 | |
| SCHEMBL3213042 | 0.87 | PLK1 (0.62) | PLK1EGLN1ALDH1A1RAB9AHDAC1 | |
| SCHEMBL13491369 | 0.87 | EGLN1 (0.67) | ROCK2PLK1EGLN1HDAC1HDAC6 | |
| SCHEMBL1680284 | 0.87 | LMNA (0.64) | PLK1EGLN1ALDH1A1RAB9AHDAC1 | |
| SCHEMBL13804470 | 0.87 | PLK1 (0.59) | ROCK2PLK1EGLN1ALDH1A1RAB9A | |
| SCHEMBL5331622 | 0.87 | LMNA (0.62) | PLK1EGLN1ALDH1A1RAB9AMAPT | |
| SCHEMBL13491381 | 0.87 | PLK1 (0.55) | PLK1EGLN1ALDH1A1RAB9AHDAC1 | |
| SCHEMBL13491384 | 0.86 | ALOX15 (0.55) | ROCK2ROCK1PLK1EGLN1ALDH1A1 | |
| SCHEMBL1681275 | 0.86 | PLK1 (0.57) | PLK1EGLN1ALDH1A1RAB9AHDAC1 | |
| SCHEMBL13491460 | 0.86 | PLK1 (0.54) | PLK1EGLN1ALDH1A1RAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2215062-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | Sumitomo Chemical Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| WO-2009069792-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | WO | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | ROCK2 3999/4885ROCK1 3049/4885PLK1 928/4885 |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | ROCK2 3131/4885ROCK1 2131/4885PLK1 294/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | ROCK2 4058/4885ROCK1 3005/4885PLK1 1133/4885 |
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | ROCK2 1020/4885ROCK1 1137/4885PLK1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.